Biotech Stock for Options Bears to Target Right Now

Core Viewpoint - Crispr Therapeutics Inc's stock rally in June is showing signs of reversal, with shares down 0.6% at $42.69, indicating a potential end to a seven-day winning streak and a historically bearish signal on the charts [1]. Group 1: Stock Performance - The stock has approached its 260-day moving average, currently within 0.75 of the trendline's 20-day average true range (ATR), after spending at least 80% of the last 10 days and two months below this average [2]. - Historical data shows that after similar signals in the past three years, CRSP was lower one month later 80% of the time, averaging an 8% loss, which could bring shares below the $40 level [3]. Group 2: Options Activity - There has been significant bullish activity in options for Crispr Therapeutics, with a ratio of 14.50 calls bought for every put in the last two weeks, indicating a higher level of optimism than 99% of readings from the past year [5].